Prostate Cancer

Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.

Episode 13 - Final Insights
May 20, 2014 – 
During the conclusion of this panel discussion, the panelists provide their final insights about managed care's role in castration-resistant prostate cancer.
Episode 12 - Specialty Pharmacy's Role in CRPC
May 20, 2014 – 
During this segment, the panelists discuss specialty pharmacy's role in urology and explore how this shift in care creates hurdles for providers and their patients.
Episode 11 - Personalized Medicine in CRPC
April 22, 2014 – 
During this segment, the panelists review the use of personalized medicine in castration-resistant prostate cancer.
Episode 10 - End-of-Life Care in CRPC
April 22, 2014 – 
During this segment, the panelists consider the variables and programs that assist providers when they counsel and care for patients during end-of-life scenarios.
Episode 9 - Benefit Design and Making Treatment Affordable
March 21, 2014 – 
Dr Dunn introduces the discussion of benefit design, suggesting that managed care providers may be unprepared to administer specialty drugs.
Episode 8 - Impact of Payment Reform on Prostate Cancer Treatment
March 21, 2014 – 
Dr Dunn invites fellow panelists to discuss the role of payment reform in managing prostate cancer. He suggests that better-aligned incentives will allow payers and providers to make better decisions about medications or other treatment options.
Episode 7 - Treatment Coverage in Castration-Resistant Prostate Cancer
February 19, 2014 – 
During this segment, the panelists explore issues faced by managed care during treatment coverage decisions in castration-resistant prostate cancer (CRPC).
Episode 6 - Treatment Response Rates in Step Therapy
February 19, 2014 – 
During this segment, David Quinn, MD, and Michael Kolodziej, MD, discuss ways to address poor treatment response among patients with castration-resistant prostate cancer who require step therapy.
Episode 5 - Pharmacoeconomic Considerations
January 10, 2014 – 
During this segment, the panelists continue discussing the rapid development of specialty drugs for the treatment of castration-resistant prostate cancer and determine the importance for a drug sequencing plan.
Episode 4 - Treatment Guidelines and Economic Considerations
January 10, 2014 – 
During this segment, Raoul S. Concepcion, MD, discusses the rapid development of expensive agents for castration-resistant prostate cancer and explains how treatment costs create a challenge to clinicians and payers. Michael Kolodziej, MD, responds by explaining what variables payers consider when making decisions about treatment coverage.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.